Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

2.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

PMID:
30092199
3.

Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition.

Schroeder HA, Nunn KL, Schaefer A, Henry CE, Lam F, Pauly MH, Whaley KJ, Zeitlin L, Humphrys MS, Ravel J, Lai SK.

Mucosal Immunol. 2018 Jul 9. doi: 10.1038/s41385-018-0054-z. [Epub ahead of print]

PMID:
29988116
4.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy295. [Epub ahead of print]

PMID:
29982718
5.

ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.

Yang B, Schaefer A, Wang YY, McCallen J, Lee P, Newby JM, Arora H, Kumar PA, Zeitlin L, Whaley KJ, McKinley SA, Fischer WA 2nd, Harit D, Lai SK.

J Infect Dis. 2018 Aug 14;218(6):901-910. doi: 10.1093/infdis/jiy230.

PMID:
29688496
6.

Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.

Kaplan FS, Zeitlin L, Dunn SP, Benor S, Hagin D, Al Mukaddam M, Pignolo RJ.

Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.

PMID:
29241828
7.

PLS3 Deletions Lead to Severe Spinal Osteoporosis and Disturbed Bone Matrix Mineralization.

Kämpe AJ, Costantini A, Levy-Shraga Y, Zeitlin L, Roschger P, Taylan F, Lindstrand A, Paschalis EP, Gamsjaeger S, Raas-Rothschild A, Hövel M, Jiao H, Klaushofer K, Grasemann C, Mäkitie O.

J Bone Miner Res. 2017 Dec;32(12):2394-2404. doi: 10.1002/jbmr.3233. Epub 2017 Sep 6.

PMID:
28777485
8.

Susceptibility and Lethality of Western Equine Encephalitis Virus in Balb/c Mice When Infected by the Aerosol Route.

Phelps AL, O'Brien LM, Eastaugh LS, Davies C, Lever MS, Ennis J, Zeitlin L, Nunez A, Ulaeto DO.

Viruses. 2017 Jun 27;9(7). pii: E163. doi: 10.3390/v9070163.

9.

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA.

Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.

10.

Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.

Anderson DJ, Politch JA, Zeitlin L, Hiatt A, Kadasia K, Mayer KH, Ruprecht RM, Villinger F, Whaley KJ.

AIDS. 2017 Jul 17;31(11):1505-1517. doi: 10.1097/QAD.0000000000001521. Review.

11.

Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, Anderson DJ, Moss JA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02465-16. doi: 10.1128/AAC.02465-16. Print 2017 Jul.

12.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

13.

How to turn competitors into collaborators.

Saphire EO, Dye JM, Kobinger GP, Zeitlin L, Chandran K, Garry RF.

Nature. 2017 Jan 18;541(7637):283-285. doi: 10.1038/541283a. No abstract available.

PMID:
28102273
14.

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.

Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB.

Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.

15.

The emergence of antibody therapies for Ebola.

Hiatt A, Pauly M, Whaley K, Qiu X, Kobinger G, Zeitlin L.

Hum Antibodies. 2015 Dec 23;23(3-4):49-56. doi: 10.3233/HAB-150284. Review.

PMID:
27472862
16.

Humanized Monoclonal Antibody That Passively Protects Mice against Systemic and Intranasal Ricin Toxin Challenge.

Van Slyke G, Sully EK, Bohorova N, Bohorov O, Kim D, Pauly MH, Whaley KJ, Zeitlin L, Mantis NJ.

Clin Vaccine Immunol. 2016 Sep 6;23(9):795-9. doi: 10.1128/CVI.00088-16. Print 2016 Sep.

17.

Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3.

Tsekoa TL, Lotter-Stark T, Buthelezi S, Chakauya E, Stoychev SH, Sabeta C, Shumba W, Phahladira B, Hume S, Morton J, Rupprecht CE, Steinkellner H, Pauly M, Zeitlin L, Whaley K, Chikwamba R.

PLoS One. 2016 Jul 18;11(7):e0159313. doi: 10.1371/journal.pone.0159313. eCollection 2016.

18.

Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.

Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM.

J Virol. 2016 Aug 12;90(17):7618-27. doi: 10.1128/JVI.00406-16. Print 2016 Sep 1.

19.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

20.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

21.

Two-mAb cocktail protects macaques against the Makona variant of Ebola virus.

Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Fausther Bovendo H, Bello A, Li F, Ye P, Jacobs M, Ippolito G, Saphire EO, Bi S, Shen B, Gao GF, Zeitlin L, Feng J, Zhang B, Kobinger GP.

Sci Transl Med. 2016 Mar 9;8(329):329ra33. doi: 10.1126/scitranslmed.aad9875.

22.

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.

Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA.

Virology. 2016 Mar;490:49-58. doi: 10.1016/j.virol.2016.01.004. Epub 2016 Jan 30.

23.

Antibody therapeutics for Ebola virus disease.

Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP.

Curr Opin Virol. 2016 Apr;17:45-49. doi: 10.1016/j.coviro.2016.01.006. Epub 2016 Jan 27. Review.

24.

CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.

Pettit DK, Rogers RS, Arthur K, Brodsky Y, Clark RH, Crowell C, Ennis J, Gillespie A, Gillespie R, Livingston B, Nalbandian E, Pace D, Smidt P, Pauly M, Timmons K, Trentalange M, Whaley KJ, Zeitlin L, Thomas JN.

MAbs. 2016;8(2):347-57. doi: 10.1080/19420862.2015.1127492.

25.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ.

J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.

26.

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Oct 9;11(10):e1005212. doi: 10.1371/journal.ppat.1005212. eCollection 2015 Oct. No abstract available.

27.

Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.

Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF.

Cell Rep. 2015 Sep 29;12(12):2111-20. doi: 10.1016/j.celrep.2015.08.038. Epub 2015 Sep 10.

28.

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Jun 26;11(6):e1005016. doi: 10.1371/journal.ppat.1005016. eCollection 2015 Jun. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005212. Berry, Jody [corrected to Berry, Jody D].

29.

Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.

Levinson KJ, Giffen SR, Pauly MH, Kim DH, Bohorov O, Bohorova N, Whaley KJ, Zeitlin L, Mantis NJ.

J Immunol Methods. 2015 Jul;422:111-7. doi: 10.1016/j.jim.2015.04.001. Epub 2015 Apr 9.

30.

Structures of protective antibodies reveal sites of vulnerability on Ebola virus.

Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17182-7. doi: 10.1073/pnas.1414164111. Epub 2014 Nov 17.

31.

A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin.

Sully EK, Whaley K, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly M, Velasco J, Holtsberg FW, Stavale E, Aman MJ, Tangudu C, Uzal FA, Mantis NJ, Zeitlin L.

Toxicon. 2014 Dec 15;92:36-41. doi: 10.1016/j.toxicon.2014.09.006. Epub 2014 Sep 28.

32.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

33.

Prevention and treatment of Clostridium perfringens epsilon toxin intoxication in mice with a neutralizing monoclonal antibody (c4D7) produced in Nicotiana benthamiana.

Garcia JP, Beingesser J, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly M, Velasco J, Whaley K, Zeitlin L, Roy CJ, Uzal FA.

Toxicon. 2014 Sep;88:93-8. doi: 10.1016/j.toxicon.2014.06.012. Epub 2014 Jun 17.

34.

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7. doi: 10.1073/pnas.1402458111. Epub 2014 Apr 7.

35.

Chimeric plantibody passively protects mice against aerosolized ricin challenge.

Sully EK, Whaley KJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Pauly MH, Velasco J, Hiatt E, Morton J, Swope K, Roy CJ, Zeitlin L, Mantis NJ.

Clin Vaccine Immunol. 2014 May;21(5):777-82. doi: 10.1128/CVI.00003-14. Epub 2014 Feb 26.

36.

Plant-Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease.

Hiatt A, Whaley KJ, Zeitlin L.

Microbiol Spectr. 2014 Feb;2(1):AID-0004-2012. doi: 10.1128/microbiolspec.AID-0004-2012. Review.

PMID:
26082108
37.

Antibody-based concepts for multipurpose prevention technologies.

Whaley KJ, Zeitlin L.

Antiviral Res. 2013 Dec;100 Suppl:S48-53. doi: 10.1016/j.antiviral.2013.09.027. Epub 2013 Nov 1. Review.

38.

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG.

Sci Transl Med. 2013 Aug 21;5(199):199ra113. doi: 10.1126/scitranslmed.3006608.

39.

Multiantibody strategies for HIV.

Hiatt A, Zeitlin L, Whaley KJ.

Clin Dev Immunol. 2013;2013:632893. doi: 10.1155/2013/632893. Epub 2013 Jun 6. Review.

40.

Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.

Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE Jr, Piedra PA, Gilbert BE.

MAbs. 2013 Mar-Apr;5(2):263-9. doi: 10.4161/mabs.23281. Epub 2013 Feb 8.

41.

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109. Epub 2012 Oct 15.

42.

Emerging antibody-based products.

Whaley KJ, Morton J, Hume S, Hiatt E, Bratcher B, Klimyuk V, Hiatt A, Pauly M, Zeitlin L.

Curr Top Microbiol Immunol. 2014;375:107-26. doi: 10.1007/82_2012_240. Review.

PMID:
22772797
43.

Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome.

Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, Roy CJ, Sidhu SS, Aman MJ.

J Biol Chem. 2012 Jul 20;287(30):25203-15. doi: 10.1074/jbc.M112.364075. Epub 2012 May 29.

44.

Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit.

O'Hara JM, Whaley K, Pauly M, Zeitlin L, Mantis NJ.

Vaccine. 2012 Feb 8;30(7):1239-43. doi: 10.1016/j.vaccine.2011.12.058. Epub 2011 Dec 22.

45.

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, Olinger GG.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20690-4. doi: 10.1073/pnas.1108360108. Epub 2011 Dec 5.

46.

Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody.

Castilho A, Bohorova N, Grass J, Bohorov O, Zeitlin L, Whaley K, Altmann F, Steinkellner H.

PLoS One. 2011;6(10):e26040. doi: 10.1371/journal.pone.0026040. Epub 2011 Oct 24.

47.

Emerging antibody products and Nicotiana manufacturing.

Whaley KJ, Hiatt A, Zeitlin L.

Hum Vaccin. 2011 Mar;7(3):349-56. Epub 2011 Mar 1. Review.

48.

Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems.

Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, Velasco J, Whaley K, Zeitlin L, Garger SJ, White E, Bai Y, Haydon H, Bratcher B.

Plant Biotechnol J. 2010 Jun;8(5):638-54. Review.

PMID:
20514694
49.

High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system.

Huang Z, Phoolcharoen W, Lai H, Piensook K, Cardineau G, Zeitlin L, Whaley KJ, Arntzen CJ, Mason HS, Chen Q.

Biotechnol Bioeng. 2010 May 1;106(1):9-17. doi: 10.1002/bit.22652.

50.

Second-generation HIV microbicides: continued development of griffithsin.

Zeitlin L, Pauly M, Whaley KJ.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6029-30. doi: 10.1073/pnas.0902239106. Epub 2009 Apr 8. No abstract available.

Supplemental Content

Loading ...
Support Center